Cellnovo Group

Cellnovo Group SA was a medical technology company focused on the diabetes management market. Founded in 2002 and headquartered in Paris, France, the firm set out to develop a comprehensive, mobile-first system for diabetic patient care. The company's flagship product was the Cellnovo System, an all-in-one diabetes management platform. This system featured a discreet, wearable micropump for insulin delivery that communicated via Bluetooth with a dedicated, locked-down Android smartphone. This handset also contained an integrated blood glucose meter, creating a singular device for tracking and treatment.

A key feature of the Cellnovo platform was its connectivity. The system was designed to automatically transmit patient data in real-time, allowing for continuous monitoring by family members and healthcare professionals. This aimed to provide peace of mind and facilitate better management of the patient's condition. The business model centered on the sale of the hardware system—the pump and handset—and the recurring revenue from proprietary insulin cartridges. The company targeted the global market for insulin pumps, which was estimated to be worth over $2 billion. After obtaining a CE Mark, the product was commercialized in several countries, including France, the UK, the Netherlands, and Australia.

Despite showing strong sales growth in its final year of operation, with revenues more than doubling in 2018 after scaling up production of its insulin cartridges , Cellnovo faced significant operational hurdles. In March 2019, the company announced it was ceasing manufacturing and commercial operations. Sophie Baratte, who was the CEO at the time, cited challenges in scaling up production in a competitive and cost-pressured market as the primary reason for this decision. The company's UK subsidiary entered administration, and the parent company in France subsequently filed for judicial liquidation in April 2019 after failing to find a buyer for the entire group. The majority of the group's assets, including its intellectual property, were held by its UK subsidiary, Cellnovo Limited.

Keywords: diabetes management, insulin pump, medtech, mobile health, remote patient monitoring, blood glucose meter, Cellnovo System, digital health, connected device, medical device, type 1 diabetes, healthcare technology, wearable tech, chronic disease management, telemedicine, CE Mark, insulin delivery system, mHealth, eHealth, judicial liquidation